Key result
Aliskiren effectively reduces blood pressure and demonstrates favorable effects on target organ damage, such as left ventricular hypertrophy and proteinuria, in hypertensive patients.
Why the study?
Does aliskiren improve blood pressure control and provide cardio-renal protection in hypertensive patients with multiple risk factors?
Does aliskiren improve blood pressure control and provide cardio-renal protection in hypertensive patients with multiple risk factors?
Aliskiren is an effective and safe direct renin inhibitor for hypertension management, offering potential cardio-renal protective benefits that may be independent of blood pressure lowering.
Supports aliskiren for BP control and target organ protection in hypertension; leaves open confirmation in prospective RCTs.
The renin-angiotensin-aldosterone system (RAAS) is an important mediator of blood pressure (BP) and volume regulation in both normotensive and hypertensive persons and is a major contributor to hypertension-related target organ damage. The concept of renin inhibition for managing hypertension by blocking the RAAS pathway at its point of activation is very attractive since the renin-angiotensinogen reaction is the first and rate-limiting step in the generation of angiotensin II (Ang II). Aliskiren, the first in a new class of orally effective direct renin inhibitors (DRIs), is approved for the treatment of hypertension. It is effective in reducing BP in the general population of hypertensive patients and in special patient groups such as obese persons, and has a tolerability and safety profile similar to placebo. Aliskiren has renoprotective, cardioprotective and anti-atherosclerotic effects in animal models that appear to be independent of BP lowering. It reduces proteinuria in diabetic patients and has favorable neurohumoral effects in patients with symptomatic heart failure. Additional outcome trials are needed to establish the role of this novel class of antihypertensive medication in the therapeutic armamentarium.
No takes yet. Share an insight, caveat, or question.
Oparil et al. (2009) conducted a review in Hypertension. Aliskiren was evaluated. Aliskiren effectively reduces blood pressure and demonstrates favorable effects on target organ damage, such as left ventricular hypertrophy and proteinuria, in hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: